At a glance
ClinicalIndex Comparison RecordN/ARecruiting· 220 target
Drug / intervention
Not specified
Likely dose
Not stated in record
Key inclusion· 5
- ✓Aged 18 years or older
- ✓Primary rectal cancer with pathological confirmation
- ✓Treated with neoadjuvant chemoradiotherapy
- ✓Clinical complete response ycT0N0 determined by clinical exam and DW-MRI
Key exclusion· 4
- ✕Recurrent rectal cancer
- ✕Contraindications for MRI
- ✕Unable to understand or read Dutch
- ✕Unable or unwilling to comply with intensive follow-up schedule
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT03426397N/ARecruitingUpdate OverdueUpdated 71mo ago · Completion was 61mo agoEnrollment Stalled
Long Recruiting
Update Overdue
Multicentre Evaluation of the "Wait-and-see" Policy for Complete Responders After Chemoradiotherapy for Rectal Cancer
In Brief
An observational study for Rectal Neoplasms. Currently recruiting, targeting 220 participants across 14 sites in 2 countries.
Signals
Enrollment appears stalled
Detailed Summary
The aim of this prospective observational cohort study is to provide short and long term oncological and functional outcome data on organ preserving treatment in good responders after a standard indication for neoadjuvant (chemo)radiation for rectal cancer.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRectal Neoplasms
CountriesBelgium, Netherlands
CollaboratorsDutch Cancer Society
Timeline
N/ARecruitingOverdue
201820192020202120222023202420252026
Enrollment StartMay 2017
First PostedFeb 2018
Primary CompletionJun 2021
Study CompletionJun 2026
TodayJul 2026
First PostedFeb 8, 2018
Enrollment StartMay 10, 2017
Primary CompletionJun 1, 2021
Study CompletionJun 1, 2026
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 8.4 years ago